NNVCNYSEPharmaceutical PreparationsFiscal year ends June 30

NANOVIRICIDES, INC.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 28, 2026

$1.30−0.08 (-5.80%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Nanoviricides has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Announcements Nanoviricides filed with the SEC

Jul 30, 2026, 6:02 AM ET
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct
Material agreement · Other events · EX-99.1 to Form 8-K
May 20, 2026, 4:30 PM ET
NanoViricides Announces Pricing of ~$2 Million Registered Direct
Material agreement · Other events · EX-99.1 to Form 8-K
May 20, 2026, 4:30 PM ET
NanoViricides Announces Closing of ~$2 Million Registered Direct
Material agreement · Other events · EX-99.2 to Form 8-K
Nov 14, 2025, 4:37 PM ET
NanoViricides Announces Pricing of $6 Million Registered Direct
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Nov 14, 2025, 4:37 PM ET
Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K

Parsed from the XBRL in Nanoviricides's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Sep 24, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing